References
- Galluzzo M, D’Adamio S, Bianchi L, et al. Psoriasis in pregnancy: case series and literature review of data concerning exposure during pregnancy to ustekinumab. J Dermatolog Treat. 2018;3:1–5.
- Lund T, Thomsen SF. Use of TNF-inhibitors and ustekinumab for psoriasis during pregnancy: a patient series. Dermatol Ther. 2017;30:e12454.
- Andrulonis R, Ferris LK. Treatment of severe psoriasis with ustekinumab during pregnancy. J Drugs Dermatol. 2012;11:1240–1241.
- Cortes X, Borrás-Blasco J, Antequera B, et al. Ustekinumab therapy for Crohn's disease during pregnancy: a case report and review of the literature. J Clin Pharm Ther. 2017;42:234–236.
- Rowan CR, Cullen G, Mulcahy HE, et al. Ustekinumab drug levels in maternal and cord blood in a woman with Crohn’s disease treated until 33 weeks gestation. J Crohns Colitis. 2018;12:376–378.
- Galli-Novak E, Mook SC, Buning J, et al. Successful pregnancy outcome under prolonged ustekinumab treatment in a patient with Crohn’s disease and paradoxical psoriasis. J Eur Acad Dermatol Venereol. 2016;30:e191–e192.
- Bobotsis R, Gulliver WP, Monaghan K, et al. Psoriasis and adverse pregnancy outcomes: a systematic review of observational studies. Br J Dermatol. 2016;175:464–472.
- Murase JE, Chan KK, Garite TJ, et al. Hormonal effect on psoriasis in pregnancy and post partum. Arch Dermatol. 2005;141:601–606.
- Chambers CD, Johnson DL. Emerging data on the use of anti-tumor necrosis factor-alpha medications in pregnancy. Birth Defects Res Part A Clin Mol Teratol. 2012;94:607–611.
- Chaudrey KH, Kane SV. Safety of immunomodulators and anti-TNF therapy in pregnancy. Curr Treat Options Gastroenterol. 2015;13:77–89.
- Weber-Schoendorfer C, Oppermann M, Wacker E, et al. Pregnancy outcome after TNF-α inhibitor therapy during the first trimester: a prospective multicentre cohort study. Br J Clin Pharmacol. 2015;80:727–739.
- Ruiz V, Manubens E, Puig L. Psoriasis in pregnancy: a review (I). Actas Dermosifiliogr. 2014;105:734–743.
- Porter ML, Lockwood SJ, Kimball AB. Update on biologic safety for patients with psoriasis during pregnancy. Int J Womens Dermatol. 2017;3:21–25.
- Addis A, Sharabi S, Bonati M. Risk classification systems for drug use during pregnancy: are they a reliable source of information? Drug Saf. 2000;23:245–253.
- Yeilding N, Szapary P, Brodmerkel C, et al. Development of the IL-12/23 antagonist ustekinumab in psoriasis: past, present, and future perspectives-an update. Ann N Y Acad Sci. 2012;1263:1–12.